|[April 11, 2014]
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
VIENNA, Va. --(Business Wire)--
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology
company, today announced that it intends to offer and sell common stock
and six month warrants in a "best efforts" underwritten public offering.
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed.
Dawson James Securities, Inc, and Laidlaw & Company (UK) Ltd. are acting
as joint book-running managers and underwriters for the proposed
A shelf registration statement and accompanying base prospectus on Form
S-3 relating to the securities was filed with the Securities and
Exchange Commission and is effective. The offering may be made only by
means of a prospectus, copies of which may be obtained, when available,
from the offices of Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th
Floor, New York, NY, 10036, telephone: 212-953-4900, or from Dawson
James Securities, 1 North Federal Highway, Suite 500, Boca Raton, FL
33432, telephone: 561-391-5555.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securiies laws of any such jurisdiction.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving
the treatment of cancer and other diseases by utilizing the immune
system, the body's natural defense system. Its lead investigational
therapy is Multikine (Leukocyte Interleukin, Injection), currently being
studied in a pivotal global Phase III clinical trial. CEL-SCI is also
investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment
for H1N1 hospitalized patients and as a vaccine (CEL-2000) for
Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS
technology platform. The investigational immunotherapy LEAPS-H1N1-DC
treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu
(H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible emergence of a new more virulent hybrid virus through
the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company
has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
*Multikine is the trademark that CEL-SCI has registered for this
investigational therapy, and this proprietary name is subject to FDA
review in connection with its future anticipated regulatory submission
for approval. Multikine has not been licensed or approved for
sale, barter or exchange by the FDA or any other regulatory
agency. Similarly, its safety or efficacy has not been established for
any use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational therapy
Multikine (Leukocyte Interleukin, Injection). Further research is
required, and early-phase clinical trial results must be confirmed in
the well-controlled, Phase III clinical trial of this investigational
therapy that is currently in progress.
Safe Harbor Statement
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Forward-looking statements include,
without limitation, the company's ability to complete the proposed
public offering of its common stock and warrants described above. Such
statements are subject to risks and uncertainties which could cause
actual results to differ materially from those projected. The Company
undertakes no obligation to publicly release the result of any revision
to these forward-looking statements which may be made to reflect the
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
[ InfoTech Spotlight's Homepage ]